Quoin Pharmaceuticals, Ltd. (QNRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Quoin Pharmaceuticals, Ltd. on October 29, 2024. The Company is incorporated in Israel and its American Depositary Shares (ADS) trade on The Nasdaq Stock Market LLC under the symbol "QNRX". The report addresses a deficiency regarding Nasdaq listing requirements.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance status regarding stock price.
Material Changes and Listing Status
- Deficiency Notice: On April 29, 2024, the Company received notice of non-compliance with Nasdaq Listing Rule 5550(a)(2) due to a failure to maintain a minimum bid price of $1.00 per ADS.
- Initial Compliance Period: The Company was granted an initial 180-day period to regain compliance, ending October 28, 2024.
- Extension Granted: On October 29, 2024, Nasdaq granted the Company an additional 180-day grace period to regain compliance, extending the deadline to April 28, 2025.
- Conditions for Extension: The extension was granted because the Company met the market value of publicly held shares requirement and all other initial listing standards, excluding the minimum bid price. The Company indicated an intention to cure the deficiency, potentially via a reverse stock split.
- Current Status: There is no immediate effect on the listing or trading of the Company's common stock.
Outlook, Risks, and Contingencies
To regain compliance during the second 180-day period, the closing bid price of the ADSs must be at or above $1.00 for a minimum of ten consecutive business days. If compliance is not achieved by April 28, 2025, Nasdaq will notify the Company that its securities will be delisted. The Company may appeal this determination to a Hearings Panel, which historically views a near-term reverse split as the definitive plan to resolve minimum bid price deficiencies. Management intends to actively monitor the bid price and consider available options to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of QNRX ADSs relative to the $1.00 threshold.
- Monitor for any future announcements regarding a proposed reverse stock split.
- Confirm the Company's continued compliance with the market value of publicly held shares requirement.
- Review the April 28, 2025 deadline for final compliance to avoid potential delisting.